Over the last 7 days, the United States market has experienced a 2.7% drop, yet it has risen by 23% over the past year with earnings expected to grow by 17% annually. In this context, growth stocks with high insider ownership can offer unique insights into potential opportunities as insiders may have confidence in their company's future prospects and are often aligned with shareholder interests.

Top 10 Growth Companies With High Insider Ownership In The United States

Name	Insider Ownership	Earnings Growth
Uxin (UXIN)	34.3%	74.1%
Upstart Holdings (UPST)	14.1%	58.1%
SharonAI Holdings (SHAZ)	32.5%	105.4%
QT Imaging Holdings (QTI)	23.9%	104.2%
Karman Holdings (KRMN)	15.6%	52.6%
FirstSun Capital Bancorp (FSUN)	21%	54.2%
Figure Technology Solutions (FIGR)	26.8%	54.1%
Corcept Therapeutics (CORT)	11.7%	48.9%
Astera Labs (ALAB)	10.3%	29.3%
AppLovin (APP)	27.5%	21.7%

Let's take a closer look at a couple of our picks from the screened companies.

ACM Research (ACMR)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: ACM Research, Inc. develops, manufactures, and sells capital equipment in Mainland China and internationally, with a market cap of approximately $5.27 billion.

Operations: The company's revenue is primarily derived from its Semiconductor Equipment and Services segment, totaling $960.23 million.

Insider Ownership: 11.2%

Revenue Growth Forecast: 19.2% p.a.

ACM Research demonstrates characteristics of a growth company with high insider ownership, despite recent volatility. The firm's revenue is projected to grow at 19.2% annually, outpacing the US market average. Earnings are expected to rise significantly by 25.3%, surpassing market expectations. However, Q1 2026 results showed a decline in net income to US$17.31 million from US$20.38 million a year earlier, and its P/E ratio of 61.2x remains below industry norms following a recent $149.99 million equity offering.

Clover Health Investments (CLOV)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Clover Health Investments, Corp. offers Medicare Advantage plans in the United States and has a market cap of approximately $2.02 billion.

Operations: The company generates revenue primarily from its insurance segment, which reported $2.21 billion.

Insider Ownership: 21.7%

Revenue Growth Forecast: 17.2% p.a.

Clover Health Investments showcases potential for growth with substantial insider ownership. Recent Q1 2026 earnings revealed a significant revenue increase to US$749.19 million and a net income of US$27.33 million, marking a turnaround from the previous year's loss. Despite trading below estimated fair value, Clover's forecasted revenue growth of 17.2% annually surpasses the broader market average, while profitability is anticipated within three years, supported by strategic partnerships enhancing interoperability in healthcare data exchange.

EagleRock Land (EROK)

Simply Wall St Growth Rating: ★★★★★☆

Overview: EagleRock Land, LLC operates as a land management company with a market cap of $2.78 billion.

Operations: The company's revenue segment includes Oil Well Equipment & Services, generating $72.17 million.

Insider Ownership: 12.4%

Revenue Growth Forecast: 29.6% p.a.

EagleRock Land demonstrates potential as a growth entity with significant insider ownership. Despite reporting a net loss of US$73.07 million for 2025, revenue surged by over 300% to US$72.17 million. The company recently completed an IPO raising US$320.05 million, indicating strong market interest. Forecasts suggest revenue will grow at 29.6% annually, outpacing the broader market, and profitability is expected within three years amid trading below estimated fair value and highly illiquid shares.

Summing It All Up

• Click here to access our complete index of 175 Fast Growing US Companies With High Insider Ownership.
• Ready For A Different Approach? AI is about to change healthcare. These 131 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.